Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05366322 · ClinicalTrials.gov registry record
A Study to Compare mRNA-1273 Versus BNT162b2 COVID-19 Vaccines Among Immunocompromised Adults
A clinical trial, sponsored by ModernaTX.
- Completed
- Registry status
- 124,879
- Enrollment target
NCT05366322 is a clinical trial that has completed, run by ModernaTX. The registered enrollment target is 124,879 participants.
The verdict
NCT05366322 has completed, sponsored by ModernaTX.
- COMPLETED
- Registry status
- 124,879 participants
- Enrollment target
Study Summary
The goal of this study is to compare real-world effectiveness of the mRNA-1273 vaccine versus the BNT162b2 vaccine on medically attended COVID-19 and COVID-19 hospitalizations among fully vaccinated immunocompromise participants.
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 124,879 participants |
| Start Date | 2021-09-10 |
| Est. Completion | 2022-03-21 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05366322
The ClinicalTrials.gov registry entry for NCT05366322 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 124,879 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is ModernaTX, which has 90 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 0 interventions.
NCT05366322 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT05366322 about?
NCT05366322 is a clinical study titled "A Study to Compare mRNA-1273 Versus BNT162b2 COVID-19 Vaccines Among Immunocompromised Adults". The goal of this study is to compare real-world effectiveness of the mRNA-1273 vaccine versus the BNT162b2 vaccine on medically attended COVID-19 and COVID-19 hospitalizations among fully vaccinated immunocompromise participants.
What is the current status of trial NCT05366322?
This trial is currently completed. The enrollment target is 124,879 participants. The study started on 2021-09-10. Estimated completion is 2022-03-21.
Who is sponsoring clinical trial NCT05366322?
This trial is sponsored by ModernaTX, which has 90 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.